Podcasts about arpa h

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

In this episode of Voices of Otolaryngology, host Rahul K. Shah, MD, MBA, AAO-HNS/F EVP and CEO, talks with Michael C. Topf, MD, MSCI, a head and neck surgical oncologist at Vanderbilt University Medical Center. Dr. Topf shares his groundbreaking work in precision head and neck surgery, including 3D scanning of resected cancer specimens to improve communication among multidisciplinary cancer care teams. The conversation explores his innovative research on specimen-based margin assessment, the development of custom software for annotating 3D models, and his team's pioneering work with intraoperative PET-CT scanning. Dr. Topf also discusses his recent $2.5 million ARPA-H grant for optical lightsheet microscopy, the importance of deep margin assessment in head and neck cancer, and offers invaluable advice to early-career researchers about navigating the competitive funding landscape. A son of an otolaryngologist himself, Dr. Topf reflects on his journey from Rochester to Stanford and Vanderbilt, and the clinical unmet needs that drive his research vision. Helpful Resources: Submit your CORE Letter of Intent by December 15, 2025, at 11:59 pm (ET): www.entnet.org/quality-practice/research/core-grants-program/2026-core-funding-opportunity-announcements/

How often do you think about the air your projects are asking people to breathe? In this episode of I Hear Design, host Robert Nieminen unpacks why indoor air quality (IAQ) has become a frontline design issue—from post-pandemic health concerns and wildfire smoke to rising expectations for healthier workplaces. Unpacking insights from articles published in interiors+sources and BUILDINGS, along with recent research, Robert walks through breakthrough initiatives like ARPA-H's BREATHE program and Mayo Clinic's HAIQU project, as well as the new Global Commission on Healthy Indoor Air launched at the United Nations, and explains what they mean for architects, interior designers, and facilities professionals. You'll learn practical strategies for improving IAQ across planning, building systems, interiors, and existing building retrofits along with real-world scenarios and key questions to bring to your next client meeting. If you're looking to connect wellness, resilience, and performance in your projects, this episode is your IAQ playbook.

When David Fajgenbaum nearly died of Castleman disease for the fifth time, he decided to take fate into his own hands. Using his medical training, he searched for an existing drug that might save his life—and found one. Now his organization, Every Cure, is scaling the same approach to uncover hidden treatments for other diseases with no known cure. David and Claudia discussed: How Every Cure is using AI to test 75 million possible disease-drug combinations The perverse incentives that keep generic drug repurposing in the shadowsWhy the hardest part of innovation isn't discovery, it's getting proven treatments into clinical practiceRepurposing existing drugs makes so much sense. But as David points out, there's no market for it:“Once a drug is generic.. the price is going to plummet… And even if you were to double the sales of your drug because you found a new disease area, now you've gone from 1% to 2% of what you got before… So there's no incentive whatsoever for our system to find a new use for a generic drug. Zero incentive.”Relevant LinksLearn more about Every CureRead David's book Chasing My Cure: A Doctor's Race to Turn Hope Into ActionWatch David's TEDTalk Listen to David's Podcast interview with Adam GrantGet info on the Dada2 FoundationWatch a video on Matt Might's story About Our GuestDavid Fajgenbaum, MD, MBA, MSc, is co-Founder & President of Every Cure and a physician-scientist at the University of Pennsylvania, where he is one of the youngest faculty members ever to receive tenure at Penn Medicine. He is also the national bestselling author of Chasing My Cure: A Doctor's Race to Turn Hope Into Action, which is being adapted into a film by Forrest Gump producer Wendy Finerman. During medical school, Fajgenbaum discovered a treatment that saved his own life and founded the Castleman Disease Collaborative Network. He has advanced 13 more repurposed treatments for cancers and rare diseases and co-founded Every Cure to unlock more hidden cures from existing medicines which has received over $100M from ARPA-H and TED's Audacious Project. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA. One of the youngest recipients of multiple top NIH and FDA grants, Fajgenbaum has authored over 100 scientific papers in leading journals, including The New England Journal of...

Alix Mayer, Board Chair and President of Free Now Foundation, California's leading medical freedom law nonprofit, joins the program to expose how government-backed initiatives like ARPA-H are building what could be called a “Weaponized Architecture for Total Dominance and Surveillance.” We discuss the detail of how surveillance systems, digital tracking, and biomedical data projects are converging into a unified control grid—one that threatens privacy, autonomy, and the very foundation of medical freedom.Learn more about Alix Mayer at https://freenowfoundation.orgSee exclusives and more at https://SarahWestall.Substack.com

Dr. Susan Monarez was the first CDC Director to be confirmed by the Senate and served from July 31, 2025 – August 27, 2025. Because she refused to give approval to new vaccine recommendations without ever seeing them or their evidence and firing scientists without cause, she was fired. In my view, she's a hero for standing up for science and speaking truth to power.In her first live interview since leaving the CDC, we review her background. That includes growing up in rural Wisconsin and getting her college and PhD education at UW-Madison, the latter in microbiology and immunology. She then went on to 18 years of government service with an extensive portfolio of jobs and management at BARDA, the White House, ARPA-H, and others, before becoming Acting Director of the CDC in early 2025.We discussed the horrific CDC shooting on August 8th, days after she started. Then we reviewed a conversation that we had on August 19th in which she laid out her exciting vision for the future of CDC, emphasizing the goal of prevention (BTW, CDC stands for Centers for Disease Control and Prevention) and asked me to help as an advisor. At the time, she was well aware, with growing tension, that her tenure at CDC might be limited. I asked about her perspective for the jobs of 4,300 people at CDC who have been terminated, which account for more than 1/3rd of the workforce, no less the gutting of the budget.Then we got into what she learned from this ordeal and her plans for the future, which includes a very ambitious initiative: 90/90/2035. As you'll see from our conversation, Dr. Monarez is exceptionally resilient and an optimist. She's got lots to do in the years ahead to carry out her mission of promoting human health!Dr. Monarez just started a Substack The Road Best Traveled so you can follow her there. It was a real privilege for me to do this interview with her. In deep admiration of her willingness to not only take on the job of CDC Director in tough circumstances, her professionalism during testimony at the Senate committee hearing, her impressive yet unrealized vision for transforming the CDC, and refusing to cave to immense pressure from the HHS Secretary to move ahead with his agenda. Thank you Julie, Stephen B. Thomas, PhD, David Dansereau, MSPT, Dr. Sara Wolfson, Vau Geha, and >500 others for tuning into my live video with The Road Best Traveled! Thanks for being a Ground Truths subscriber! Please spread the word. Get full access to Ground Truths at erictopol.substack.com/subscribe

Alix Mayer, Board Chair and President of Free Now Foundation, California's leading medical freedom law nonprofit, joins the program to expose how government-backed initiatives like ARPA-H are building what could be called a “Weaponized Architecture for Total Dominance and Surveillance." We discuss the detail of how surveillance systems, digital tracking, and biomedical data projects are converging into a unified control grid—one that threatens privacy, autonomy, and the very foundation of medical freedom.Learn more about Alix Mayer at https://freenowfoundation.orgSee exclusives and more at https://SarahWestall.Substack.comRelief band: For 20% off your order, head to https://Reliefband.com and use code SARAH.Purchase the most effective weight peptide available, Next Generation GLP-1 Retatrutide - use code Sarah to save 15%: https://www.limitlesslifenootropics.com/product/retatrutide-ha/?ref=vbWRE3JSee the peptide guide for the most effective weight loss and muscle preservation at https://sarahwestall.substack.com/p/the-ultimate-peptide-guide-for-weightProtect your assets with a company you can trust - Get the private & better price list - Go to https://SarahWestall.com/MilesFranklinCopyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.Disclaimer: "As a journalist, I report what significant newsmakers are claiming. I do not have the resources or time to fully investigate all claims. Stories and people interviewed are selected based on relevance, listener requests, and by suggestions of those I highly respect. It is the responsibility of each viewer to evaluate the facts presented and then research each story furtherSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

우리가 꿈꾸는 기적을 현실로! ‘아무리 희귀한 난치병도 고칠 수 있는 치료약이 있다면?', ‘어떤 암도 조기에 발견해 완치될 수 있다면?', ‘나이가 들어도 죽는 날까지 건강하게 살 수 있다면?' 모두가 꿈꾸는 기적을 현실로 만들기 위해 치열한 고민과 도전을 이어가는 사람들이 있다. 해결하기 어렵지만, 세상에 꼭 필요한 ‘난제'들을 풀기 위해 실패와 도전 그리고 혁신을 반복하는 이들을 만난다. 단 한 명만을 위한 맞춤형 치료, 'N of 1'의 힘 5살 라온이는 ‘선천성 당단백질 형성 이상증'이라는 희귀질환을 앓고 있다. 돌연변이 유전자로 인해 태어날 때부터 소뇌가 작았는데, 자라면서 더 작아질 수 있고 건강에도 악영향을 줄 수 있다는 것이다. 치료약도, 치료법도 없는 상황에서 그저 지금의 상태가 유지되기만을 바라며 지냈는데, 최근 뜻밖의 제안을 받게 됐다. 라온이만을 위한 맞춤형 치료제를 만들어 보자는 것이다. 실제로 미국에서는 단 한 명만을 위한 맞춤 치료제가 만들어진 일이 있다. 돌연변이 유전자로 인해 뇌세포가 손상되며 시력과 운동 능력, 인지 기능을 잃어가던 6살 소녀, ‘밀라(Mila)'만을 위해 ‘밀라센(milasen)'이라는 치료제가 개발된 것이다. ‘왜 굳이 단 한 사람만을 위한 치료제가 필요할까?' 이런 의문이 들 수도 있지만, 한 사람을 위한 치료 과정에서 쌓이는 지식과 경험은 다른 환자들에게도 도움이 되며, 결국 ‘N of 1'이 ‘N of many'가 되고, 결국 ‘N of more'가 될 수 있다. 1%의 성공 가능성에 도전하는 사람들 사실 밀라센 프로젝트가 가능할 수 있었던 건, 보건 의료 분야의 난제를 해결하기 위한 정부의 의지와 지원 덕분이다. 미국은 지난 2022년, 달 착륙 임무 등 혁신적 연구의 아이콘인 미 국방부 산하 연구기관 DARPA에서 착안해 보건, 의료 분야 도전 혁신 연구를 지원하는 ‘ARPA-H'를 만들었다. 우리도 지난해 한국형 ‘ARPA-H'로 불리는 ‘K-헬스미래추진단'을 신설하고 보건, 의료 분야의 난제를 해결하기 위한 다양한 도전과 혁신을 시도하고 있다. 단 한 사람만을 위한 맞춤형 치료제 개발부터 피 한 방울로 극초기에 암을 발견하고, 우주에서 신약을 개발하는 도전까지~ 그동안 누구도 가보지 않은 길에서 고군분투하며 K보건, K의료의 새로운 미래를 개척하고 있다. 이번 주 특별기획 에서는 우리가 꿈꾸는 미래를 위해 1%의 성공 가능성에 도전하는 이들을 만나보고, 그 도전을 현실로 만들기 위해 필요한 조건은 무엇인지 살펴본다.

Global elites are still pushing forward with their Great Reset agenda to enslave the world and create a post-human future despite President Trump's crushing of ESG and DEI, researcher and author Whitney Webb tells Glenn. In her long-awaited return to "The Glenn Beck Podcast," Whitney explores the intricate web of global elites, including the World Economic Forum's downfall under Klaus Schwab and current state under Larry Fink as well as the rise of digital IDs and AI-driven governance like Albania's “digital minister.” Whitney also discusses the tools she believes the Great Reset elites are building to control us, including the Biden-era ARPA-H program and possible surveillance tech tied to Palantir and the CIA. Further, Whitney ties the globalists' agenda to the chaos happening in cities like Chicago and Portland and what Trump must be wary of when deploying the National Guard. Plus, as a leading expert in the financial crimes and corrupt connections of Jeffrey Epstein, Whitney weighs in on the debate over the “black book” and why the government still hasn't released all the Epstein documents.   You can read Whitney Webb's latest reporting on the Epstein case HERE: https://unlimitedhangout.com/author/whitney-webb/   Sponsors: American Financing's salary-based mortgage consultants are saving their customers an average of $800 a month! Call American Financing at 800-906-2440 or go to https://AmericanFinancing.net.   If you're living with aches and pains, see how Relief Factor, a daily drug-free supplement, could help you feel better and live better. Try the 3-week QuickStart for just $19.95 by visiting https://ReliefFactor.com.   Right now, to celebrate 25 years in business, Moxie Pest Control is offering your first pest control service for just $25. Visit https://MoxieServices.com/BECK and use promo code “BECK.”   The Atom X hearing aid from Audien is a beautifully designed, ready-to-go device made by audiologists who actually listened to what people want — less clutter, less confusion, less fiddling around. Visit https://AudienHearing.com and take control of your hearing today.   Learn more about your ad choices. Visit megaphone.fm/adchoices

The AI Cyber Challenge, AIxCC, marks a pivotal inflection point for cyber defense.Numerous attacks in recent years have illuminated the ability for malicious cyber actors to exploit vulnerable software that runs everything from financial systems and public utilities to the health care ecosystem.AIxCC Competitors successfully demonstrated the ability of novel autonomous systems using AI to secure the open-source software that underlies critical infrastructure, with winners revealed at DEF CON 33.Hear from DARPA and ARPA-H on the game-changing results the competitors achieved.And although the competition is over, the challenge continues. All seven finalist teams' CRSs have been made available as open-source software under a license approved by the Open Source Initiative.Hear from teams on their experiences through the competition and how they are moving their systems to the real world.LINKS:Competition websiteFinalist teamsOpen source archiveInformation Innovation OfficeARPA-H Resilient Systems Office

In this eye-opening episode, we sit down with Julia Komissarchik, CEO and Co-Founder of Glendor Inc., to explore the rapidly evolving intersection of AI in healthcare, medical data privacy, and patient data protection. With AI transforming clinical decision-making, diagnostics, and health research, traditional privacy approaches like de-identification are no longer sufficient.Julia, a seasoned expert in AI and a multi-patent holder, explains why anonymised health data is still vulnerable to re-identification by AI models, and how privacy-preserving technologies like federated learning, differential privacy, homomorphic encryption, and secure multi-party computation can help.She discusses real-world breaches, regulatory challenges with HIPAA and GDPR, and the importance of patient consent and ethical AI governance. This episode is a must-listen for AI researchers, health tech entrepreneurs, data scientists, hospital CIOs, privacy advocates, and anyone navigating the future of AI-powered healthcare.Key Topics Covered:Why traditional anonymisation methods are failing in the age of AI-driven healthcareHow AI models can re-identify patients using "innocuous" data like medication patterns and X-ray imageryThe risks and limitations of synthetic data in clinical AI developmentThe critical role of federated learning, differential privacy, and homomorphic encryptionWhy current HIPAA and GDPR regulations may be falling short for modern healthcare applicationsThe urgent need for multi-modal data sharing frameworks that are both privacy-conscious and research-enablingReal-world examples of data privacy breaches and their financial and reputational consequencesInspiring success stories from ARPA-H's INDEX initiative and South Korea's AI health data sharing modelThe call for a new era of algorithmic transparency, AI ethics, and patient empowerment in health data useAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it's being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI's role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta has released new safety data for their gene therapy Elevidys, showing zero ambulatory deaths in patients with Duchenne muscular dystrophy. This data confirms the therapy's positive risk/benefit profile. Meanwhile, Novo Nordisk's rapid rise and fall was driven by GLP-1s like Ozempic and Wegovy, leading to a plummet in stock value. Insmed has received FDA approval for the first bronchiectasis drug and DPP1 blocker, Brinsupri. Texas has accused Eli Lilly of "bribing" prescribers to push their drugs Mounjaro and Zepbound, leading to a new lawsuit. Genscript is entering a new era of innovation and trust, offering exclusive promos and events. Additionally, Tang Capital is on a buyout binge in the biotech industry, while a top ARPA-H official has departed in protest of cuts to mRNA funding. The biotech industry continues to see contractions with companies like AbSci, Fate, and Oric downsizing. In career advice, loyalty is seen as a flawed strategy that can cost individuals opportunities.Arrowhead, a biotech company, has emerged as a savior in the RNA interference (RNAi) pipeline after Sarepta faced troubles unrelated to Arrowhead's assets. Concentra Biosciences, a biotech shell company, has been on a buying spree, acquiring four biotechs in the past month and seven so far this year. President Trump's most favored nation drug pricing policy is seen as unfavorable for all parties involved. Novo Nordisk experienced a rapid rise and fall due to the success of ozempic and wegovy. Lilly is facing drug pricing pressure while defending its injectable GLP-1 empire. Novartis is rumored to be considering acquiring RNA specialist Avidity. Despite safety concerns, Sarepta beat Q2 estimates, but not due to sales of its product Elevidys. Various biotech companies are downsizing while others are receiving significant investments.

On this episode of Soundbites of the Annual Meeting, we talked to Mimi Lee, MD, PhD, a physician-scientist and program manager at the Advanced Research Projects Agency for Health (ARPA-H). In her conversation with ASGCT's Communications Committee Chair, Lynnea Olivarez, Dr. Lee discusses: ARPA-H's unique approach to funding and structuring CGT development breaking down silos to improve health outcomes for all the role that CGT will play in prevention, rather than just treatment, of diseases Listen and subscribe to the ASGCT Podcast Network so you don't miss any episodes!Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Send us a textCheck us out at:  https://www.cisspcybertraining.com/Get access to 360 FREE CISSP Questions:  https://www.cisspcybertraining.com/offers/dzHKVcDB/checkoutReady to master data classification for your CISSP exam? This episode delivers exactly what you need through fifteen practical questions that mirror real exam scenarios, all focused on Domain 2.1.1.The cybersecurity world is constantly evolving, and our discussion of the newly formed ARPA-H demonstrates this perfectly. Modeled after DARPA but focused on healthcare innovation, this agency represents a $50 million opportunity for security professionals to tackle the persistent ransomware threats plaguing the healthcare industry.Diving into our practice questions, we explore how marketing materials receive "sensitive" classifications, while revolutionary battery technology blueprints warrant "class three severe impact" protection. We clarify why social security numbers in healthcare settings fall under Protected Health Information rather than just PII, and why government agencies use distinctive classification schemas including terms like "top secret" that aren't merely arbitrary labels.The episode tackles complex scenarios including cloud storage responsibilities (you retain ownership of customer data even when stored by third parties), the limitations of DLP solutions for printed documents, and proper breach response protocols. Each question provides context-rich explanations that go beyond simple answers to build your understanding of the underlying principles.Perhaps most valuable is our exploration of classification system design - revealing why simply labeling all non-public information as "sensitive" creates security vulnerabilities by failing to distinguish between different impact levels. This practical insight helps you not just memorize concepts but understand how to implement effective classification in real-world environments.Whether you're studying for your CISSP exam or wanting to strengthen your organization's security posture, these fifteen questions provide the perfect framework for mastering data classification principles. Visit cisspcybertraining.com to access our complete blueprint and mentoring services guaranteed to help you pass the CISSP exam on your first attempt.Gain exclusive access to 360 FREE CISSP Practice Questions delivered directly to your inbox! Sign up at FreeCISSPQuestions.com and receive 30 expertly crafted practice questions every 15 days for the next 6 months—completely free! Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

This week on H-SPAN, we are joined by Dr. Andrew Brack, Program Manager at the Advanced Research Projects Agency for Health (ARPA-H)In this episode, we discuss Andrew's unique journey that led him to the longevity space, what PROSPR is doing to move the industry forward, and how ARPA-H can serve as a catalyst for healthspan innovation.

What if a government agency could fund transformative health research with $200 million budgets and no bureaucratic committees? In this talk, Jean Hebert explores ARPA-H's – a research funding agency – unique mission to accelerate health breakthroughs, from 3D-printed organs to functional eye transplants. He covers how ARPA-H operates differently from traditional government funding through autonomous program managers, why it presents exceptional opportunities for longevity researchers, and how both established scientists and entrepreneurs can engage with this well-funded agency that's aligned with life extension goals.Jean Hebert is a professor of genetics and neuroscience, and the author of "Replacing Aging". He currently serves as a Program Manager at ARPA-H. His personal mission remains unchanged: to beat aging, which he believes is achievable through replacement therapies and transformative approaches to life extension.This talk was recorded at Vision Weekend US 2024. To see the slides and more talks from the event, please visit our Youtube channel. Hosted on Acast. See acast.com/privacy for more information.

In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what's changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.   Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC's Kenan-Flagler Business School. Editing and post-production work for this episode was provided by The Podcast Consultant.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Time Stamps:2:00 - Siemens Executives Die in Helicopter Crash11:03 - ARPA-H and the AI Healthcare Revolution41:14 - Larry Ellison = Trump's Media Mogul?1:02:15 - US & Iran Negotiations/Regime Change in Iran?1:12:11 - Ukraine/Russia Truce Violations1:16:59 - REAL ID Requirement1:45:53 - "The Maniac Murder Cult"Welcome to The Morning Dump, where we dive headfirst into the deep end of the pool of current events, conspiracy, and everything in between. Join us for a no-holds-barred look at the week's hottest topics, where we flush away the fluff and get straight to the substance.Please consider supporting our work-Austin's Patreon: https://www.patreon.com/c/TheUnderclassPodcastAustin's Spreaker: https://www.spreaker.com/podcast/the-underclass-podcast--6511540Austin's Rumble: https://rumble.com/user/TheUnderclassPodcastAustin's YouTube: https://www.youtube.com/@TheUnderclassPodcastCheck out nadeaushaveco.com today & use code Jose for 10% off your entire order!!!Jose's Patreon- https://www.patreon.com/nowayjose2020 Only costs $2/month and will get you access to episodes earlier than the public Check out TopLobsta's kickass threads- toplobsta.com Use JOSE at checkout for 10% off Get No Way, Jose! merch- https://www.toplobsta.com/pages/no-way-joseNo Way, Jose! Rumble Channel- https://rumble.com/c/c-3379274No Way, Jose! Odysee Channel- https://odysee.com/@NoWayJose:7?r=JChxx9RMmW9PuL49z3PvTq4sxE2GjJrpNo Way, Jose! YouTube Channel- https://youtube.com/channel/UCzyrpy3eo37eiRTq0cXff0gJose's Podcast Host- https://redcircle.com/shows/no-way-joseApple podcasts- https://podcasts.apple.com/us/podcast/no-way-jose/id1546040443Spotify- https://open.spotify.com/show/0xUIH4pZ0tM1UxARxPe6ThStitcher- https://www.stitcher.com/show/no-way-jose-2Amazon Music- https://music.amazon.com/podcasts/41237e28-c365-491c-9a31-2c6ef874d89d/No-Way-JoseGoogle Podcasts- https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5yZWRjaXJjbGUuY29tL2ZkM2JkYTE3LTg2OTEtNDc5Ny05Mzc2LTc1M2ExZTE4NGQ5Yw%3D%3DRadioPublic- https://radiopublic.com/no-way-jose-6p1BAOVurbl- https://vurbl.com/station/4qHi6pyWP9B/#REALIDRequirement #ManiacMurderCult #MKU #MKY #O9A #TrumpAssassinationPlot #NikitaCasap #SiemensCrash #HelicopterTragedy #SiemensExecutives #ARPAHTranshumanism #AIHealthcareRevolution #DARPATV #InternetOfBodies #MRNABioWeapon #ModernEugenics #AIGovernance #PredictiveMedicine #LarryEllison #TrumpMediaMogul #EllisonTrump #EllisonTikTok #USIranTalks #IranRegimeChange #IranNegotiations #TruceViolations #RussiaUkraineConflictBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-underclass-podcast--6511540/support.

In this episode of Lab Rats to Unicorns, we welcome Dede Willis, co-founder and CEO of Orbit Genomics, a trailblazer in the field of diagnostics and life sciences. With a background in aerospace engineering and over 25 years of leadership experience, Dede shares how her engineering mindset and entrepreneurial resilience have driven her to build impactful startups that tackle complex challenges. Dede dives into the mission of Orbit Genomics, exploring how they're harnessing the potential of “junk DNA” to revolutionize cancer detection and save lives. She also opens up about the challenges of securing funding in the diagnostics space, the importance of fostering team diversity, and the pivotal role government programs like ARPA-H and Cancer Moonshot play in advancing healthcare innovation. Through thoughtful storytelling and actionable insights, Dede reveals how diagnostics can complement therapeutics, why collaboration is essential to progress, and how startups can thrive by embracing resilience and adaptability. This episode is an inspiring testament to the power of persistence, innovation, and building bridges in science and beyond.

The Advanced Research Projects Agency - Health, known as ARPA-H, is tiny at only 118 employees. Its personnel needs are highly specific, though. ARPA-H has used a variety of strategies to get the people it needs. The Government Accountability Office finds, the agency needs a more organized approach. More now from the GAO's director of science, technology assessment and analytics, Candice Wright. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Advanced Research Projects Agency - Health, known as ARPA-H, is tiny at only 118 employees. Its personnel needs are highly specific, though. ARPA-H has used a variety of strategies to get the people it needs. The Government Accountability Office finds, the agency needs a more organized approach. More now from the GAO's director of science, technology assessment and analytics, Candice Wright. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Andrew Brack, Program Manager at the Advanced Research Projects Agency for Health (ARPA-H), discusses PROSPR (Proactive Solutions for Prolonging Resilience), an ambitious new program aimed at extending human healthspan. In this wide-ranging conversation, Chris and Andrew explore how PROSPR plans to accelerate the development of therapies that target aging itself by building the regulatory and scientific infrastructure needed to measure and improve health during aging. They discuss PROSPR's innovative approaches to in-home data collection, biomarker development, and clinical trial design that could compress decades-long studies into just three years.The Finer Details:The mission and structure of ARPA-H as a catalyst for healthcare innovationHow PROSPR aims to build "train tracks" for the longevity therapeutics industryThe program's novel approach to measuring health through intrinsic capacityStrategies for compressing clinical trials from decades to yearsThe economic impact of extending healthspan by just one yearPlans for first- and second-generation therapeutics targeting agingThe role of in-home health monitoring in future clinical trialsQuote: "We have this moral imperative to close the gap between the length that we are living and the number of years that we're living in good health."Links:PROSPR websiteProposers' Day registration

President Joe Biden will issue a memo and framework on the use of AI in the context of national security Thursday, with the aim of providing steps for U.S. leadership and guardrails for governance of the technology. Under the memo, agencies will be directed to access “the most powerful AI systems and put them to use,” senior administration officials who briefed reporters on the memo ahead of its release said. The memo will also bolster the role of the AI Safety Institute and provide direction to agencies for AI use for national security. The Advanced Research Projects Agency for Health, known as ARPA-H, is seeking information about how autonomous artificial intelligence systems, known as agentic AI, might be used in the health care space. A recent request for information posted by the Department of Health and Human Services agency specifically asks for information on implementations of agentic AI, how multiple agentic AI systems work together, scalability, risks, and how autonomy is decided, among other things. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast on on Apple Podcasts, Soundcloud, Spotify and YouTube.

The Advanced Research Projects Agency-Health, ARPA-H, has launched two new programs aimed at the kinds of tough problems the agency specializes in. One deals with artificial intelligence models to predict drug safety. The other with computation systems needed to design vaccines. Details now from ARPA-H program manager Dr. Andy Kiliansk https://arpa-h.gov/news-and-events/arpa-h-launches-program-develop-predictive-drug-safety-and-efficacy-models https://arpa-h.gov/news-and-events/arpa-h-announces-awards-develop-computational-platform-multi-virus-vaccine-design Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Advanced Research Projects Agency-Health, ARPA-H, has launched two new programs aimed at the kinds of tough problems the agency specializes in. One deals with artificial intelligence models to predict drug safety. The other with computation systems needed to design vaccines. Details now from ARPA-H program manager Dr. Andy Kilianskhttps://arpa-h.gov/news-and-events/arpa-h-launches-program-develop-predictive-drug-safety-and-efficacy-modelshttps://arpa-h.gov/news-and-events/arpa-h-announces-awards-develop-computational-platform-multi-virus-vaccine-design Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Advanced Research Projects Agency for Health (ARPA-H) has launched a new program providing health care organizations a rapid and secure cyber solution that will protect their infrastructure from threats and prevent disruptions in patient care. ARPA-H Resilient Systems Program Manager Andrew Carney discusses the Universal Patching Intermediation for Autonomous Defense (UPGRADE) program and how it offers medical facilities protection from ransomware attacks by automatically providing proactive and scalable updates to their IT systems. Carney highlighted another ARPA-H program called the Digital Health Security Initiative (DIGIHEALS) that's addressing vulnerabilities in data security. He also shared details about the agency's collaborative efforts with its defense counterpart, DARPA.

Artificial intelligence has penetrated deeply into the world of medical devices. The DA has approved nearly a thousand AI-enabled medical gadgets. Given that nature of AI, the question must be asked: How to keep these devices working properly overtime. That's a question the Advanced Research Projects Agency for Health seeks to answer. For details, we turn to ARPA-H program manager Berkman Sahiner. Learn more about your ad choices. Visit megaphone.fm/adchoices

Artificial intelligence has penetrated deeply into the world of medical devices. The DA has approved nearly a thousand AI-enabled medical gadgets. Given that nature of AI, the question must be asked: How to keep these devices working properly overtime. That's a question the Advanced Research Projects Agency for Health seeks to answer. For details, we turn to ARPA-H program manager Berkman Sahiner. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Government systems often take a lot of flack for their (sometimes) built-in inability to take risks and make big bets. So, what would it take to encourage the government to take those big, risky moonshots? For Health, that's the role of ARPA-H – to fund new ways of improving health by investing in people with big ideas. We sat down with ARPA-H Director Renee Wegrzyn at Aspen Ideas Health to talk about how it's going and what comes next. We discuss:Why ARPA-H is personal for President Biden.How ARPA-H's special authorities – from flexible hiring to novel contracting – are its secret weapons for speed and scale.The critical role of Program Managers – single decision maker driving the vision and execution of each $50-$200 million initiative.Renee says ARPA-H gives her the ability to direct funds into areas that are sometimes left off the list of “must haves” for innovation:“...one of the only top down things I've done as a director is said, ‘Why aren't we funding more in women's health? We don't have any program managers in the pipeline that want to exclusively focus on this'. But I think we all inherently understand that women are underrepresented in almost every aspect of health. So I asked our [Program Managers].. who wants to raise [a] hand and pick a topic that is really either unique to women, or is disproportionately affecting women that we can do a sprint and invest around. And so I got six Program Managers to come up with topics, everything from Women's Health at home, to brain health, to understanding and quantifying pain – and through the Investor Catalyst Hub we have worked with investors to understand what kind of convincing scale do we need to get to for you to be the second investor. And we competed this across the country.”Relevant LinksAbout ARPA-H ARPA-H Health Equity Factsheet The Minor Consult Podcast EpisodeARPA - H TimelineYoutube Conversation with New Yorker writerWhite House FAQ Sheet on ARPA-HAbout Our GuestDr. Renee Wegrzyn is the first director of the Advanced Research Projects Agency for Health (ARPA-H), appointed by President Biden on October 11, 2022. Previously, she was the Vice President of Business Development at Ginkgo Bioworks and Head of Innovation at Concentric by Ginkgo, where she focused on synthetic biology for combating infectious diseases like COVID-19.Wegrzyn has experience with DARPA and IARPA, the models for ARPA-H. At DARPA, she used synthetic biology and gene editing to enhance biosecurity and the bioeconomy, managing programs like Living Foundries, Safe Genes, PREPARE, and DIGET. She received the Superior Public Service Medal for her DARPA work. Her career includes leading biosecurity and gene therapy teams in private industry, developing immunoassays and diagnostics. Wegrzyn has served on various scientific advisory boards, including those for the National Academies and the Air Force Research Labs. She holds a Ph.D. and a bachelor's degree in applied biology from the Georgia Institute of Technology and completed...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viral vector manufacturers are facing challenges such as high production expenses, low titers, empty capsids, and limited scalability when producing cell and gene therapies. To overcome these challenges, they are turning to next generation production processes to create a cost-effective and robust AAV manufacturing process. This new approach aims to produce higher titers and full capsids, increase efficiencies resulting from high yields, and drive down the cost per dose. By implementing these strategies, manufacturers can improve the productivity of AAV production and bring promising treatments to the market more effectively.Embecta received FDA approval for its insulin patch pump, featuring a larger insulin reservoir based on feedback from people with type 2 diabetes. Meanwhile, Illumina avoided a fine for its acquisition of Grail in a European court victory. The ARPA-H program will focus on AI degradation in medical tools, while a pathology group is suing to block an FDA lab test rule. Additionally, Medtronic's chief medical officer of acute care and monitoring has departed for a new role.The text discusses various updates in the biopharma industry as of September 3, 2024. It covers topics such as the next challenger to Prevner, advancements in AI drug discovery, concerns over suicide risk of obesity drugs, Recursion's lead drug safety, Vaxcyte's positive data for a pneumococcal vaccine, Sanofi's mixed results in MS drug trials, and the value of digital insights in pharma success.A new study predicts a healthcare labor shortage by 2028, with certain states and specialties facing acute shortages. The study also reveals disparities in fighting medical bills, as uninsured and less educated patients are less likely to question their bills. The ARPA-H program will focus on addressing AI degradation in medical tools. Other updates include tracking healthcare worker strikes and data breaches. The use of technology is transforming healthcare to combat challenges such as workforce shortages and shifting care utilization patterns.FDA Commissioner Dr. Robert Califf is considering reforms to advisory committees, including potentially scrapping expert voting in some circumstances. Califf believes that the discussions within these committees may be more valuable to the FDA than the final vote outcomes. Eliminating voting could help clarify the role of advisory committees. Other potential reforms being discussed include addressing conflicts of interest.The text discusses the importance of getting the Institutional Review Board (IRB) review right the first time and introduces a checklist of critical questions to ask potential IRB partners to ensure a smoother review process. By asking the right questions and choosing the right IRB, the review process can be more efficient and effective.Novo Nordisk's drug Ozempic will continue to face shortages into the fourth quarter due to supply issues, even as the company tries to expand its indication. Astellas Gene Therapies is closing its biomanufacturing facility in San Francisco, affecting about 100 employees and shifting manufacturing to North Carolina.In a landscape where consumers are willing to switch brands to save money, it is crucial for brands to establish and maintain loyalty among shoppers. By leading with value, moving consumers from awareness to loyalty to advocacy, and creating connection and community, brands can build brand love even in the face of economic pressures.The text discusses how emerging oncology innovations have led to more effective therapies for cancer patients. The increased investment in cancer research has introduced new treatments such as cell and gene therapies, antibody drug conjugates, and checkpoint inhibitors. Despite these advancements, the industry still faces challenges in expanding access and improving outcomes.

Don Kinzler shares fall gardening tips. Dr. Renee Wegrzyn discusses ARPA-H's bold health initiatives on "Conversations on Health Care" and and Chuck Lura explores North Dakota's iconic sunflowers.

August 5, 2024: Wes Wright, Chief Healthcare Officer at Ordr, and Mac McMillan, Founder, CEO, Board Member, and Advisor, join Drex for the news. The discussion highlights the persistent disparity in healthcare access between rural and urban areas, questioning whether technology alone can bridge this gap. The conversation also explores the ARPA-H initiative, pondering if new technology development is necessary when existing tools might suffice. The trio reflects on the creation of a dedicated Cyber Force, drawing parallels with military coordination to enhance cybersecurity. Should the government play a more significant role in supporting private sector defenses? They further discuss the indictment of a North Korean cybercriminal, debating the implications of such actions and the broader geopolitical context.Key Points:00:37 Rural Healthcare Challenges02:54 Technology and Socioeconomic Issues05:58 ARPA-H Initiative and Military Healthcare09:17 The Case for a Cyber Force13:54 North Korean Cyber Threats and Final ThoughtsNews articles:Microsoft and Google are helping rural hospitals protect themselves from cyberattacksUS indicts North Korean hacker accused of helping extort US hospitals | CNN PoliticsA Cyber Force Is Not the Only Solution - War on the RocksThis Week Health SubscribeThis Week Health TwitterThis Week Health LinkedinAlex's Lemonade Stand: Foundation for Childhood Cancer Donate

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs.   Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.   Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.   The conversation highlights examples of ARPA-H investments and milestones achieved, as well as the processes involved in determining future programs and investment priorities. Craig and Jenica also discuss the unique Entrepreneur in Residence (EIR) program and how it supports ARPA-H projects.   About Craig Gravitz: Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H).  Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. He is a licensed attorney and has previously serviced as a contracting officer.   About Jenica Patterson, Ph.D.: Jenica Patterson, Ph.D is a Portfolio Lead at ARPA-H within the Project Accelerator Transition Innovation Office (PATIO) and leads the Sprint for Women's Health. Formerly Dr. Patterson served as the Director of the Technology Transfer and Transition (T3X) Division in the PATIO office, where she oversaw public-private partnerships for transition and the small business program for ARPA-H. Dr. Patterson received her Ph.D in Neuroscience at the University of Maryland, Baltimore County (UMBC) and served as a Science and Technical Advisor at the Defense Advance Research Project Agency, and a Program Director at NIH prior to joining ARPA-H.   Tune in to BioTalk for an informative discussion with Craig Gravitz and Jenica Patterson as we explore the innovative work of ARPA-H and its impact on health research and development.

I discuss Crowdstrike and their history, along with the Q drops that describe their intentions and what the shutdown may have really been about; I discuss the company Palantir and the work of Whitney Webb and her dig on their connections to mass surveillance and pre-crime; I also dive briefly into their sister companies Carbyne and ARPA-H and how they are designed to surveil and socially engineer the masses to ultimately kill us.  Crowdstrike: https://archive.4plebs.org/pol/thread/474868046 Palantir https://theamericanclassroom.substack.com/p/palantir-mass-surveillance-and-pre

This podcast is about big ideas on how technology is making life better for people with vision loss. For hundreds of years, health professionals have dreamed of restoring vision for people who are blind or visually impaired. However, doing so, either through transplanting a functioning eye or using technological aids, is an incredibly complex challenge. In fact, many considered it impossible. But thanks to cutting-edge research and programs, the ability to restore vision is getting closer than ever. As a first for this podcast, this episode features an interview with Dr. Cal Roberts himself! Adapting audio from an interview on The Doctors Podcast, Dr. Cal describes his work as a program manager for a project on eye transplantation called Transplantation of Human Eye Allographs (THEA). Funded by a government initiative called ARPA-H, THEA is bringing some of the country's finest minds together to tackle the complexities of connecting a person's brain to an eye from a human donor. This episode also features an interview with Dr. Daniel Palanker of Stanford University. Dr. Palanker is working on technology that can artificially restore sight through prosthetic replacement of photoreceptors. Having proved successful in animals, Dr. Palanker and his team are working hard to translate it to humans. And if that can happen, then something once considered impossible could finally be accomplished!   The Big Takeaways The Challenges of Eye Transplants: Although eyeball transplants have been done, they've only been cosmetic. So far, nobody has been able to successfully connect a donor eyeball to a recipient's brain. Dr. Roberts's work with THEA is bringing together multiple teams to tackle the challenges associated with a whole eyeball transplant, from connecting nerves and muscles to ensuring the organ isn't rejected, and much more. “Artificial” Vision Restoration: Dr. Palanker is working to replace the functions of photoreceptors through technological means. His photovoltaic array is placed underneath the retina and can convert light into an electrical current that activates the cells that send visual information to the brain. While it doesn't completely restore sight for people with Age-Related Macular Degeneration, this technology shows incredible promise. Decoding “Brain Language”: For both Dr. Roberts and Dr. Palanker, one of the biggest challenges with vision restoration is understanding how the eye and brain communicate. Dr. Roberts likens it to Morse Code — the eye speaks to the brain in “dots and dashes,” which the brain then converts into vision. Right now, the language is still foreign to us, but we're closer than ever to decoding it. The Evolution of the Brain-Machine Interface: Dr. Palanker imagines incredible possibilities in the interaction between the brain and technology. If we can find a way to truly translate the brain's signals into information, Dr. Palanker envisions the possibility of direct brain-to-brain communication without verbalization. In a way, this could make people telepathic, able to understand and digest vast amounts of information in an instant.   Tweetables: So ideally in medicine, at least the ideal therapy is the restoration of full functionality. If we can grow back photoreceptors and make them reconnect to bipolar cells, undo all the rewiring that right now underwent during degeneration, and restore the full extent of vision, that would be the ideal outcome. — Dr. Daniel Palanker, Professor of Ophthalmology, Stanford University We can think about other aspects of brain-machine interface, which takes you maybe into the realm of capabilities that humans never had. If you enable artificial senses or enable brain-to-brain connectivity so you can communicate without verbalization that would open completely new capabilities that humanity never had. — Dr. Palanker Forty-two years after the implantation of the first mechanical heart, there's not a single person in the world walking around with a mechanical heart. All that work, all that research, and all that effort to come up with mechanical heart transplants are still state-of-the-art. And so, while I believe that there is a role for a bionic eye or mechanical eye, what I really believe is that everything that we learn from doing an eye transplant will just make it better and easier when we do eventually come up with a bionic or a mechanical eye. — Dr. Calvin Roberts, ARPA-H Health Science Futures Program Manager (President and CEO of Lighthouse Guild and Host of On Tech & Vision!)   Contact Us: Contact us at podcasts@lighthouseguild.org with your innovative new technology ideas for people with vision loss.   Pertinent Links Lighthouse Guild THEA Program Prima System   People's Choice Podcast Awards We appreciate your support for our show — and now, we need your help nominating the On Tech & Vision podcast for the People's Choice Podcast Awards! We are participating in these awards so we can showcase On Tech & Vision to a broader audience, gain recognition within the industry, and, most importantly, help spread the message about Lighthouse Guild and the role that technology is playing in tearing down barriers for people who are blind or visually impaired. To help us nominate On Tech & Vision, please go online to www.podcastawards.com, where you can register to vote for On Tech & Vision in both the Technology and Peoples' Choice Categories. Voting is open until July 31st. Once again, your support is greatly appreciated!

Host Robert Traynham is joined by Dr. Bon Ku of the Advanced Research Projects Agency for Health (ARPA-H), a new federal agency aimed at pioneering ambitious health care initiatives. Dr. Ku will talk about the PARADIGM program, rural health care, and the concept of health care design.

Director of ARPA-H, Dr. Renee Wegrzyn, joins host Jeanne Meserve for a live conversation to discuss the agency's role in investing in new and critical technologies at SCSP's AI Expo. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit scsp222.substack.com

Reid Hoffman, co-Founder of LinkedIn and Inflection AI discusses the possibilities and risks that artificial intelligence will pose over the next decade and why he believes everyone will have an AI digital agent in the future. Then, ARPA-H director, Renee Wegrzyn and MIT School of Engineering Professor of AI and Health discuss how AI is changing the health-care landscape and what the industry can do right now to implement the technology into its infrastructure. Conversation recorded on June 13, 2024 at The Futurist: The Age of AI summit.

April 8, 2024: David Ting, Founder and CTO at Tausight joins Drex DeFord, President, 229 Risk & Security at This Week Health for the news. As we delve into the conversation, Ting shares his insights on the challenges and opportunities presented by the current state of cybersecurity in healthcare, particularly in light of recent high-profile cyber events. How will increased regulations and mandates impact healthcare organizations, and is there a balance to be struck between compliance and genuine security? Ting also explores the hyperconnected nature of healthcare and the vulnerabilities it introduces. Could the solution lie in not just more regulations but in providing healthcare organizations with the necessary incentives and financial assistance to bolster their cybersecurity measures? Furthermore, we touch upon the potential of AI in revolutionizing healthcare cybersecurity, as highlighted by the partnership between ARPA H and DARPA.Key Points:Impact of Increased RegulationsFinancial Assistance and IncentivesSecuring Pediatric Health DataPartnership Between ARPA H and DARPANews articles:Processing Mismanagement: Responding to Change Healthcare's Meltdown - 4sight HealthDear Colleague Letter2 Minute Drill: Budget Dust and Cyber Urgency: A Call for Stronger Hospital SecurityRansomware attack on Change Healthcare pegged as "most significant" in sector historyThis Week Health SubscribeThis Week Health TwitterThis Week Health LinkedinAlex's Lemonade Stand: Foundation for Childhood Cancer Donate

This week on StartUp Health NOW, we have again handed over the microphones to two members of our Health Moonshot Impact Board and having them interview each other. At one end of the table we've got Margaret Laws, CEO & President of HopeLab, former Director of Innovations for the Underserved at CHCF, and Founder of the CHCF Health Innovation Fund, and at the other end of the interview table is Shirley Bergin, Senior Advisor at ARPA-H, Former CMO/COO of TEDMED, and Advisor to Ellipsis Health and Cure. The goal of the conversation was simply to hear about the latest projects and passions of two of the most influential and interesting people in health innovation. In the interview, which took place in person at the Lake Nona Impact Forum in Florida, we cover a range of topics, from youth mental health, to the role of AI in diagnostics, to education to address global gaps in the healthcare workforce. Margaret Laws and Shirley Bergin are thought leaders in health innovation, but they're also deeply involved in directing funds towards promising programs, so it will be interesting to see how their curiosities and passions as played out here will lead to concrete moves in the future. Enjoy the conversation. Innovating in Alzheimer's disease? Learn how you can join our new Alzheimer's Moonshot. Passionate about Type 1 diabetes? Learn how you can get one of the last spots in our T1D Moonshot. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

President Biden has announced a comprehensive initiative, including a new executive order aimed at revolutionizing women's health research and innovation across America. Rooted in his State of the Union vision, Biden has proposed a transformative $12 billion investment to establish a fund for Women's Health Research at NIH. This initiative, the first White House initiative on women's health research, seeks to fundamentally alter the landscape of women's health research in the U.S. and ensure comprehensive integration and prioritization within the federal research agenda. It encompasses a broad spectrum of actions, including a $200 million NIH investment for the 2025 fiscal year and the launch of ARPA-H's Sprint for Women's Health with a $100 million commitment. The initiative's directives include enhancing research across various stages of women's lives, particularly focusing on midlife health challenges and leveraging AI in health research advancements. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, we're super excited to chat with Brian Anderson, co-founder of CHAI, Coalition for Health AI, and Chief Digital Health Physician at MITRE. CHAI is a community of academic health systems, organizations, and expert practitioners of artificial intelligence and data science. Brian leads research and development efforts across major strategic initiatives in digital health, partnering with the US government and private sector companies.  Prior to joining MITRE, Anderson led the Informatics and Network Medicine Division at athenahealth, where he launched a new model of clinical decision support leveraging artificial intelligence. He has also served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). On top of all that, Brian is also a Harvard Medical School Associate Professor of Biomedical Informatics and senior advisor for ARPA-H in Clinical Trial Innovation. Anderson completed his clinical training at Massachusetts General Hospital and completed his B.A. and M.D. degrees at Harvard College and Harvard Medical School. In this episode, we talk about Brian's career journey from clinical practice to digital health, CHAI's efforts to establish AI process standards for healthcare, the concept of a federated network of assurance labs, and advice for the health AI innovation community. 

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Welcome to the daily304 – your window into Wonderful, Almost Heaven, West Virginia.   Today is Friday. Feb. 2  Looking for a good-paying and rewarding job? WV corrections facilities are hiring. Two WV chefs are semifinalists for the prestigious James Beard award. And WVU enters a new research partnership that may spark health innovation…on today's daily304. #1 – From JOBCASE – Explore a stable and rewarding career with the West Virginia Division of Corrections and Rehabilitation. As a correctional officer, you'll play a pivotal role in ensuring public safety, upholding public trust and contributing to a higher purpose. You'll be making a real impact on your community.  Higher salaries await you, starting at a minimum of $40,000 annually plus a retention bonus after one year and further salary increases after two years. You'll also receive a great benefits package and paid leave. Additional perks include paid training and plenty of advancement opportunities. What are you waiting for? Visit www.jobcase.com/ru/West-Virginia to find out who's hiring! Read more: https://www.jobcase.com/articles/wv-dcr   #2 – From WCHS-TV – Two chefs from West Virginia have been recognized for culinary excellence with James Beard Award nominations. Chef Paul Smith, of 1010 Bridge in Charleston, has been nominated for best chef of the southeast while Scott MacGregor, from Snowshoe's Appalachian Kitchen, joins the semifinalist list. “It's a huge deal,” said Smith, who was one of five finalists last year. “I wouldn't say it's a dream come true because it's beyond our wildest dreams. This is the Academy Awards for chefs, so just to be nominated you are an Academy Award-winning chef basically." “It was shocking. It was definitely exciting,” MacGregor said. “It was an honor for me to think that I'm in there with people from huge food cities, like Memphis, Nashville, Charleston, South Carolina and all of these places that are kind these up-and-running food cities. I'm here in the middle of the mountains.” Finalists will be announced in March. Read more: https://wchstv.com/news/local/two-wva-chefs-nominated-for-coveted-james-beard-awards-appalachian-kitchen-scott-macgregor-1010-bridge-paul-smith-snowshoe-charleston-culinary-west-virginia   #3 – From WVU TODAY – West Virginia University has been tapped to help accelerate commercialization of medical innovations by collaborating with a nationwide network within the National Institutes of Health. WVU is one of just 127 entities to be named a spokesmember or partner for the Investor Catalyst Hub, a regional hub of the Advanced Research Projects Agency for Health. The University is the only member from West Virginia. ARPA-H's overarching mission is to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions and resilient systems. As a member of the hub, WVU will have access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. “We will be able to tap into a wealth of knowledge and expertise that is represented through the spokes and are excited for the possibilities that will emerge from the ARPA-H partnerships,” said Erienne Olesh, executive director of the Office of Student and Faculty Innovation in the WVU Research Office.   Read more: https://wvutoday.wvu.edu/stories/2024/01/29/wvu-selected-to-partner-with-federal-research-entity-to-spark-health-innovation   Find these stories and more at wv.gov/daily304. The daily304 curated news and information is brought to you by the West Virginia Department of Commerce: Sharing the wealth, beauty and opportunity in West Virginia with the world. Follow the daily304 on Facebook, Twitter and Instagram @daily304. Or find us online at wv.gov and just click the daily304 logo.  That's all for now. Take care. Be safe. Get outside and enjoy all the opportunity West Virginia has to offer.

Texas is a large state with a huge population to take care of. With recent moves to provide better healthcare, Texas is said to be the leading state for advancing healthcare and medical education. Recently, ARPA-H, a medical innovation federal agency, has declared Dallas as one of its three national hub spaces for its medical breakthroughs in science and medicine. So, Texas wants to know, what is ARPA-H and what the hub here means for our state and Texans?

Dr. Renee Wegrzyn is the first director of the Advanced Research Projects Agency for Health, (ARPA-H), a new federal agency with a $2.5 billion budget. Modeled after DARPA, the agency is tasked with taking big risks in biomedical research that seem beyond the reach of the private sector. Dr. Wegrzyn joins Preet to discuss how ARPA-H is promoting innovation, and their goal to “end cancer as we know it.”  Stay Tuned is nominated for a Signal Award…and you're in the jury box! Head to cafe.com/signal to vote.  Stay Tuned in Brief is presented by CAFE and the Vox Media Podcast Network. Please write to us with your thoughts and questions at letters@cafe.com, or leave a voicemail at 669-247-7338. For analysis of recent legal news, join the CAFE Insider community. Head to cafe.com/insider to join for just $1 for the first month.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

From its beginnings in 1958 as the Advanced Research Projects Agency to the eventual folding into the Department of Defense in 1972 under its current acronym, DARPA has always been on the cutting edge of technological advancements in the fields of aerospace, defense, computing, and intelligence gathering. These days DARPA is best known for scary robot dogs and brain implants, but the United States government has big plans for expanding the concept of advanced research with “High-risk, High-reward” expectations into the health industry with the creation of ARPA-H in 2022 to take the medical industry where DARPA took the defense contractors. Prepare to be terrified of where this technology is headed and who ultimately has control over its usage, because the robot dogs of your nightmares are only the beginning. Freeworld NYC 9/11 Live Event Tickets: https://www.eventbrite.com/e/free-world-nyc-tickets-667727369537 American Liberty Awards: www.americanlibertyawards.com Christian Yordanov's Detoxification Program: https://members.christianyordanov.com/detox-workshop?coupon=MACRO Sponsors: Emergency Preparedness Food: www.preparewithmacroaggressions.com Chemical Free Body: https://www.chemicalfreebody.com Promo Code: MACRO C60 Purple Power: https://c60purplepower.com/ Promo Code: MACRO Wise Wolf Gold & Silver: www.Macroaggressions.gold True Hemp Science: https://truehempscience.com/ Haelan: https://haelan951.com/pages/macro Solar Power Lifestyle: https://solarpowerlifestyle.com/ Promo Code: MACRO LegalShield: www.DontGetPushedAround.com EMP Shield: www.EMPShield.com Promo Code: MACRO Coin Bit App: https://coinbitsapp.com/?ref=0SPP0gjuI68PjGU89wUv Macroaggressions Merch Store: https://www.teepublic.com/stores/macroaggressions?ref_id=22530 LinkTree: linktr.ee/macroaggressions Books: HYPOCRAZY: https://amzn.to/3VsPDp8 Controlled Demolition on Amazon: https://amzn.to/3ufZdzx The Octopus Of Global Control: Amazon: https://amzn.to/3VDWQ5c Barnes & Noble: https://bit.ly/39vdKeQ Online Connection: Link Tree: https://linktr.ee/Macroaggressions Instagram: https://www.instagram.com/macroaggressions_podcast/ Discord Link:  https://discord.gg/4mGzmcFexg Website: www.theoctopusofglobalcontrol.com Facebook: www.facebook.com/theoctopusofglobalcontrol Twitter: www.twitter.com/macroaggressio3 Twitter Handle: @macroaggressio3 YouTube: www.youtube.com/channel/UCn3

Episode 2159: The Great Reset: Live From TPUSA Phoenix; If The Regime Continues To Go Unchecked, We Will Continue To See Destruction; ARPA-H: From Healing/Enhancement, To Humanity 2.0